Impact of chronic obstructive pulmonary disease severity on symptoms and prognosis in patients with systolic heart failure

Clinical Research in Cardiology

Volumn 101, Issue 9, 2012, Pages 717-726

  Arnaudis, Brice ^a   Lairez, Olivier ^a,b,c   Escamilla, Roger ^d   Fouilloux, Audrey ^a,b   Fournier, Pauline ^a   Monteil, Benoit ^a   Bouisset, Frédéric ^a   Arnal, Jean François ^a,c   Elbaz, Meyer ^a,c   Carrié, Didier ^a,c   Roncalli, Jérôme ^a,c   Pathak, Atul ^a,e   Galinier, Michel ^a,c  

^a CHU RANGUEIL   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d SERVICE DE PNEUMOLOGIE   (France)

^e University Hospital of Toulouse   (France)

Author keywords

Chronic obstructive pulmonary disease; Dyspnoea; GOLD stage; Prognosis; Systolic heart failure

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; SPIROMETRY; SYSTOLIC HEART FAILURE;

ADULT; AGED; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSPNEA; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, SYSTOLIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPIROMETRY;

EID: 84866068505     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-012-0450-4     Document Type: Article

References (36)

1. Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW (2006) Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail 8(7):706-711 (Pubitemid 44635314)
2. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ (2009) Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 11(2):130-139
3. Mannino DM, Brown C, Giovino GA (1997) Obstructive lung disease deaths in the United States from 1979 through 1993. An analysis using multiple-cause mortality data. Am J Respir Crit Care Med 156(3 Pt 1):814-818 (Pubitemid 27396420)
4. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS (2002) Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347(18):1397-1402 (Pubitemid 35239711)
5. Finkelstein J, Cha E, Scharf SM (2009) Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis 4:337-349
6. Boudestein LC, Rutten FH, Cramer MJ, Lammers JW, Hoes AW (2009) The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail 11(12):1182-1188
7. Hawkins NM, Petrie MC, Macdonald MR, Jhund PS, Fabbri LM, Wikstrand J, McMurray JJ (2011) Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. J Am Coll Cardiol 57(21):2127-2138
8. Iversen KK, Kjaergaard J, Akkan D, Kober L, Torp-Pedersen C, Hassager C, Vestbo J, Kjoller E (2010) The prognostic importance of lung function in patients admitted with heart failure. Eur J Heart Fail 12(7):685-691
9. Kwon BJ, Kim DB, Jang SW, Yoo KD, Moon KW, Shim BJ, Ahn SH, Cho EJ, Rho TH, Kim JH (2010) Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease. Eur J Heart Fail 12(12):1339-1344
10. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De Caterina R, Dean V, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29(19):2388-2442
11. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176(6):532-555 (Pubitemid 47403272)
12. Iversen KK, Kjaergaard J, Akkan D, Kober L, Torp-Pedersen C, Hassager C, Vestbo J, Kjoller E (2008) Chronic obstructive pulmonary disease in patients admitted with heart failure. J Intern Med 264(4):361-369
13. Rusinaru D, Saaidi I, Godard S, Mahjoub H, Battle C, Tribouilloy C (2008) Impact of chronic obstructive pulmonary disease on long-term outcome of patients hospitalized for heart failure. Am J Cardiol 101(3):353-358 (Pubitemid 351162971)
14. Macchia A, Monte S, Romero M, D'Ettorre A, Tognoni G (2007) The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. Eur J Heart Fail 9(9):942-948 (Pubitemid 47332320)
15. Puri S, Dutka DP, Baker BL, Hughes JM, Cleland JG (1999) Acute saline infusion reduces alveolar-capillary membrane conductance and increases airflow obstruction in patients with left ventricular dysfunction. Circulation 99(9):1190-1196 (Pubitemid 29120091)
16. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ (2004) The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350(10):1005-1012 (Pubitemid 38269277)
17. Gorelik O, Almoznino-Sarafian D, Shteinshnaider M, Alon I, Tzur I, Sokolsky I, Efrati S, Babakin Z, Modai D, Cohen N (2009) Clinical variables affecting survival in patients with decompensated diastolic versus systolic heart failure. Clin Res Cardiol 98(4):224-232. doi: 10.1007/s00392-009-0746-1
18. Edelmann F, Stahrenberg R, Gelbrich G, Durstewitz K, Angermann CE, Dungen HD, Scheffold T, Zugck C, Maisch B, Regitz-Zagrosek V, Hasenfuss G, Pieske BM, Wachter R (2011) Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clin Res Cardiol 100(9):755-764. doi: 10.1007/s00392-011-0305-4
19. Mascarenhas J, Lourenco P, Lopes R, Azevedo A, Bettencourt P (2008) Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J 155(3):521-525 (Pubitemid 351255605)
20. Salpeter S, Ormiston T, Salpeter E (2005) Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 19(4):CD003566
21. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB (2008) Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 63(4):301-305 (Pubitemid 351497940)
22. Macie C, Wooldrage K, Manfreda J, Anthonisen N (2008) Cardiovascular morbidity and the use of inhaled bronchodilators. Int J Chron Obstruct Pulmon Dis 3(1):163-169 (Pubitemid 351523729)
23. Au DH, Udris EM, Curtis JR, McDonell MB, Fihn SD (2004) Association between chronic heart failure and inhaled β-2-adrenoceptor agonists. Am Heart J 148(5):915-920
24. Au DH, Curtis JR, Every NR, McDonell MB, Fihn SD (2002) Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest 121(3):846-851 (Pubitemid 34251453)
25. Lemaitre RN, Siscovick DS, Psaty BM, Pearce RM, Raghunathan TE, Whitsel EA, Weinmann SA, Anderson GD, Lin D (2002) Inhaled β-2 adrenergic receptor agonists and primary cardiac arrest. Am J Med 113(9):711-716 (Pubitemid 36044695)
26. Hawkins NM, MacDonald MR, Petrie MC, Chalmers GW, Carter R, Dunn FG, McMurray JJ (2009) Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail 11(7):684-690
27. Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD (2003) Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 123(6):1964-1969 (Pubitemid 36706719)
28. Bermingham M, O'Callaghan E, Dawkins I, Miwa S, Samsudin S, McDonald K, Ledwidge M (2011) Are β-2-agonists responsible for increased mortality in heart failure? Eur J Heart Fail 13(8):885-891
29. Brooks TW, Creekmore FM, Young DC, Asche CV, Oberg B, Samuelson WM (2007) Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers. Pharmacotherapy 27(5):684-690 (Pubitemid 46700960)
30. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, Elsik M, Krum H, Hayward CS (2010) Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol 55(17):1780-1787
31. Mogelvang R, Goetze JP, Schnohr P, Lange P, Sogaard P, Rehfeld JF, Jensen JS (2007) Discriminating between cardiac and pulmonary dysfunction in the general population with dyspnea by plasma pro-B-type natriuretic peptide. J Am Coll Cardiol 50(17):1694-1701 (Pubitemid 47562682)
32. Franke J, Frankenstein L, Schellberg D, Bajrovic A, Wolter JS, Ehlermann P, Doesch AO, Nelles M, Katus HA, Zugck C (2011) Is there an additional benefit of serial NT-proBNP measurements in patients with stable chronic heart failure receiving individually optimized therapy? Clin Res Cardiol 100(12):1059-1067. doi: 10.1007/s00392-011-0340-1
33. Zugck C, Franke J, Gelbrich G, Frankenstein L, Scheffold T, Pankuweit S, Duengen HD, Regitz-Zagrosek V, Pieske B, Neumann T, Rauchhaus M, Angermann CE, Katus HA, Ertl GE, Stork S (2011) Implementation of pharmacotherapy guidelines in heart failure: experience from the German Competence Network Heart Failure. Clin Res Cardiol. doi: 10.1007/s00392-011-0388-y
34. Andreas S, Anker SD, Scanlon PD, Somers VK (2005) Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest 128(5):3618-3624 (Pubitemid 41698701)
35. Sakamaki F, Satoh T, Nagaya N, Kyotani S, Nakanishi N, Ishida Y (1999) Abnormality of left ventricular sympathetic nervous function assessed by (123)I-metaiodobenzylguanidine imaging in patients with COPD. Chest 116(6):1575-1581 (Pubitemid 30012697)
36. Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, Swedberg K, Pfeffer MA, McMurray JJ, Maggioni AP (2009) Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail 11(3):292-298